Jazz Pharmaceuticals plc announced positive top-line results from their Phase 3 double-blind, multicenter, placebo-controlled, randomized withdrawal study evaluating the efficacy and safety of an investigational use of Xywav in adult patients with idiopathic hypersomnia.

Patients in the study had excessive daytime sleepiness typical of idiopathic hypersomnia. All patients were treated with Xywav and reported clinically meaningful improvements in the Epworth Sleepiness Scale (ESS).

Xywav was approved in July 2020 by the FDA for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.

To learn more about Xywav or this IH study, read the Jazz press release.